Medicare Begins Coverage of GLP-1 Drugs for Obesity: Comparing the New $50 Bridge Program vs. Cash-Pay Alternatives

The landscape of obesity treatment shifted fundamentally on July 1, 2026, as the Centers for Medicare and Medicaid Services (CMS) launched the Medicare GLP-1 Bridge program. For the first time, millions of older Americans have a federally supported pathway to access blockbuster weight-loss medications like Wegovy, Zepbound, and Foundayo. This marks a watershed moment in preventative care, translating years of clinical research into practical, accessible treatment for seniors.[1][2]

Historically, Medicare has been legally prohibited from covering drugs prescribed solely for weight loss under a 2003 statute. This created a frustrating two-tier system where GLP-1s were covered for diabetes or cardiovascular disease, but denied for pure obesity management. The new Bridge program bypasses this restriction using Section 402 demonstration authority, offering a temporary 18-month window of coverage designed to gather data and provide immediate relief.[1][2]

The financial relief for eligible patients is substantial. Under the Bridge program, beneficiaries enrolled in Medicare Part D pay a flat $50 monthly copayment for these medications, which typically retail for over $1,000 out of pocket. However, because the program operates outside the standard Part D benefit, it is important for patients to note that these copays do not count toward the $2,100 annual out-of-pocket spending cap.[1][5]

Eligibility is strictly gated to ensure the program reaches those with the highest clinical need while managing the astronomical costs associated with these drugs. An estimated 3.8 million Medicare beneficiaries qualify based on the current clinical criteria. To participate, a patient must have a Body Mass Index (BMI) of 35 or higher, or a BMI of 30 or higher coupled with specific conditions like heart failure with preserved ejection fraction or chronic kidney disease stage 3a.[1][5]

Furthermore, the program is designed exclusively for those who cannot access GLP-1s through standard Part D. Patients who already have a diagnosis of type 2 diabetes, obstructive sleep apnea, or noncirrhotic MASH are excluded from the Bridge program, as their conditions already qualify them for standard, permanent coverage under their existing plans.[1][5]

The launch of the Bridge program arrives at a critical time, as state Medicaid programs and private insurers increasingly buckle under the financial weight of GLP-1 prescriptions. Several states have recently eliminated Medicaid coverage for weight-loss drugs, citing unsustainable budget pressures and soaring pharmacy costs. This makes the federal program an essential lifeline for lower-income seniors who have been cut off from state-level support.[4]

Despite the optimism surrounding the $50 copay, the temporary nature of the program requires patients to plan ahead. The Bridge is scheduled to sunset on December 31, 2027. Patient advocacy groups and the Obesity Medicine Association continue to push for the passage of the Treat and Reduce Obesity Act (TROA), which would permanently repeal the statutory exclusion of weight-loss drugs and ensure long-term stability.[2][3]

In the meantime, the market is fracturing into distinct pathways. While the Bridge program offers a highly regulated, low-cost route for those who meet the strict criteria, a parallel ecosystem of direct-to-consumer platforms, compounded pharmacies, and cash-pay discount programs—such as the newly introduced TrumpRx—is expanding rapidly to serve those who fall outside the eligibility gates.[3]

For patients and their healthcare providers, navigating this new landscape requires a careful calculation of eligibility, out-of-pocket costs, and long-term sustainability. The decision is no longer just about whether to take a GLP-1, but which systemic pathway offers the most reliable, safe, and affordable access over time.[6]